PT3435996T - Elafibranor para utilização no tratamento de colangite biliar primária - Google Patents
Elafibranor para utilização no tratamento de colangite biliar primáriaInfo
- Publication number
- PT3435996T PT3435996T PT177133329T PT17713332T PT3435996T PT 3435996 T PT3435996 T PT 3435996T PT 177133329 T PT177133329 T PT 177133329T PT 17713332 T PT17713332 T PT 17713332T PT 3435996 T PT3435996 T PT 3435996T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- methods
- cholestatic diseases
- cholestatic
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305381 | 2016-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3435996T true PT3435996T (pt) | 2025-05-13 |
Family
ID=55661352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177133329T PT3435996T (pt) | 2016-03-31 | 2017-03-30 | Elafibranor para utilização no tratamento de colangite biliar primária |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11185519B2 (pt) |
| EP (3) | EP3435996B1 (pt) |
| JP (1) | JP7010836B2 (pt) |
| KR (1) | KR102338085B1 (pt) |
| CN (2) | CN109152756B (pt) |
| AU (1) | AU2017242819B2 (pt) |
| CA (1) | CA3018132C (pt) |
| DK (1) | DK3435996T3 (pt) |
| EA (1) | EA038386B1 (pt) |
| ES (1) | ES3030999T3 (pt) |
| FI (2) | FI3435996T3 (pt) |
| HR (1) | HRP20250776T1 (pt) |
| HU (2) | HUE071511T2 (pt) |
| IL (2) | IL261935B2 (pt) |
| LT (2) | LT3435996T (pt) |
| MD (1) | MD3435996T2 (pt) |
| MX (2) | MX388863B (pt) |
| NL (1) | NL301342I2 (pt) |
| NO (1) | NO2025045I1 (pt) |
| NZ (1) | NZ785185A (pt) |
| PH (1) | PH12018502056B1 (pt) |
| PL (1) | PL3435996T3 (pt) |
| PT (1) | PT3435996T (pt) |
| RS (1) | RS66930B1 (pt) |
| SG (1) | SG11201808222RA (pt) |
| SI (1) | SI3435996T1 (pt) |
| SM (1) | SMT202500241T1 (pt) |
| WO (1) | WO2017167935A1 (pt) |
| ZA (1) | ZA201807084B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201406155QA (en) | 2011-10-28 | 2014-11-27 | Lumena Pharmaceuticals Inc | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases |
| SG11201401849QA (en) | 2011-10-28 | 2014-05-29 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| US12053445B2 (en) * | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| CN110418641A (zh) * | 2017-02-24 | 2019-11-05 | 基恩菲特公司 | 用于组合疗法的药物组合物 |
| WO2019099761A1 (en) * | 2017-11-16 | 2019-05-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| WO2019186410A1 (en) * | 2018-03-27 | 2019-10-03 | Lupin Limited | Solid forms of elafibranor and processes thereof |
| EP3863623A1 (en) * | 2018-10-11 | 2021-08-18 | Centre national de la recherche scientifique | Treatment of diseases associated with biliary system destruction |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| EP3923943B1 (en) | 2019-02-12 | 2024-07-31 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency |
| JP2022524820A (ja) * | 2019-03-13 | 2022-05-10 | ノバルティス アーゲー | 医薬組成物 |
| JP2022527840A (ja) * | 2019-04-09 | 2022-06-06 | ジェンフィット | 免疫疾患又は炎症を治療するためのニタゾキサニド及びエラフィブラノールの組合せ |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN110548118B (zh) * | 2019-10-21 | 2021-09-14 | 江苏省中医院 | 一种具有防治原发性胆汁性胆管炎的中药复方及其制备方法与应用 |
| KR20220140762A (ko) * | 2020-02-10 | 2022-10-18 | 장피트 | 엘라피브라노에 의한 원발 담즙성 담관염의 치료 |
| EP4103546A1 (en) * | 2020-02-10 | 2022-12-21 | Genfit | Polymorphs of elafibranor |
| US20230165821A1 (en) * | 2020-05-18 | 2023-06-01 | Genfit | Elafibranor for the treatment of primary sclerosing cholangitis |
| EP4204405A4 (en) | 2020-08-25 | 2024-05-29 | Eli Lilly and Company | POLYMORPHS OF AN SSAO INHIBITOR |
| MX2023002159A (es) * | 2020-08-26 | 2023-03-01 | Genfit | Composiciones y metodos para el tratamiento de la colangitis biliar primaria. |
| EP4525845A1 (en) * | 2022-05-19 | 2025-03-26 | Tyra Biosciences, Inc. | Therapies with ppar agonists and fgfr4 inhibitors |
| US12296050B2 (en) | 2023-10-05 | 2025-05-13 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
| WO2025075624A1 (en) * | 2023-10-05 | 2025-04-10 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (fr) | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| US20070197606A1 (en) * | 2006-02-22 | 2007-08-23 | Burczynski Frank J | Use of ppar agonists as anti-oxidants |
| AU2010323066B2 (en) * | 2009-11-26 | 2014-12-11 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| CN107405325B (zh) * | 2015-02-06 | 2021-11-12 | 英特塞普特医药品公司 | 用于组合疗法的药物组合物 |
| CN110418641A (zh) * | 2017-02-24 | 2019-11-05 | 基恩菲特公司 | 用于组合疗法的药物组合物 |
-
2017
- 2017-03-30 WO PCT/EP2017/057634 patent/WO2017167935A1/en not_active Ceased
- 2017-03-30 JP JP2018550793A patent/JP7010836B2/ja active Active
- 2017-03-30 SM SM20250241T patent/SMT202500241T1/it unknown
- 2017-03-30 IL IL261935A patent/IL261935B2/en unknown
- 2017-03-30 RS RS20250623A patent/RS66930B1/sr unknown
- 2017-03-30 AU AU2017242819A patent/AU2017242819B2/en active Active
- 2017-03-30 SI SI201731612T patent/SI3435996T1/sl unknown
- 2017-03-30 EP EP17713332.9A patent/EP3435996B1/en active Active
- 2017-03-30 MX MX2018011738A patent/MX388863B/es unknown
- 2017-03-30 SG SG11201808222RA patent/SG11201808222RA/en unknown
- 2017-03-30 MD MDE20190147T patent/MD3435996T2/ro unknown
- 2017-03-30 KR KR1020187031600A patent/KR102338085B1/ko active Active
- 2017-03-30 CA CA3018132A patent/CA3018132C/en active Active
- 2017-03-30 CN CN201780020144.5A patent/CN109152756B/zh active Active
- 2017-03-30 HU HUE17713332A patent/HUE071511T2/hu unknown
- 2017-03-30 FI FIEP17713332.9T patent/FI3435996T3/fi active
- 2017-03-30 EP EP23175851.7A patent/EP4233910A3/en not_active Withdrawn
- 2017-03-30 PT PT177133329T patent/PT3435996T/pt unknown
- 2017-03-30 PL PL17713332.9T patent/PL3435996T3/pl unknown
- 2017-03-30 NZ NZ785185A patent/NZ785185A/en unknown
- 2017-03-30 MX MX2021015783A patent/MX2021015783A/es unknown
- 2017-03-30 PH PH1/2018/502056A patent/PH12018502056B1/en unknown
- 2017-03-30 ES ES17713332T patent/ES3030999T3/es active Active
- 2017-03-30 EP EP25170190.0A patent/EP4559481A3/en active Pending
- 2017-03-30 IL IL311687A patent/IL311687A/en unknown
- 2017-03-30 LT LTEPPCT/EP2017/057634T patent/LT3435996T/lt unknown
- 2017-03-30 CN CN202210467808.5A patent/CN114796237B/zh active Active
- 2017-03-30 DK DK17713332.9T patent/DK3435996T3/da active
- 2017-03-30 HR HRP20250776TT patent/HRP20250776T1/hr unknown
- 2017-03-30 US US16/090,415 patent/US11185519B2/en active Active
- 2017-03-30 EA EA201892202A patent/EA038386B1/ru unknown
-
2018
- 2018-10-24 ZA ZA2018/07084A patent/ZA201807084B/en unknown
-
2025
- 2025-09-12 NL NL301342C patent/NL301342I2/nl unknown
- 2025-09-15 LT LTPA2025535C patent/LTPA2025535I1/lt unknown
- 2025-09-22 HU HUS2500039C patent/HUS2500039I1/hu unknown
- 2025-09-23 FI FIC20250032C patent/FIC20250032I1/fi unknown
- 2025-09-30 NO NO2025045C patent/NO2025045I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| ZA201807389B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| IL253244B1 (en) | Methods for treating retinal diseases | |
| HUS2500033I1 (hu) | Intrahepatikus kolesztázisos betegségek kezelése | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| ZA201807390B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| ZA201705877B (en) | Method of treating diseases | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| ZA201808360B (en) | Treatment of intrahepatic cholestatic diseases | |
| GB201416832D0 (en) | Methods of treatment | |
| IL253847A0 (en) | Methods of treating diseases | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| HK40001765A (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| GB201504413D0 (en) | Treatment of disease | |
| GB201604253D0 (en) | Treatment of genetic diseases | |
| GB201517565D0 (en) | Treatment of genetic diseases |